Source:http://linkedlifedata.com/resource/pubmed/id/17911427
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
2007-10-3
|
pubmed:abstractText |
Hepatitis C virus (HCV) is a hepatotropic virus causing hepatocellular damage and chronic liver inflammation that progressively can lead to cirrhosis and hepatocellular carcinoma (HCC). HCV is also lymphotropic, as demonstrated by its capacity to replicate in lymphocytes, by the recurrent detection of organ- and non-organ-specific autoantibodies in HCV-infected patients, and by the strong association found between HCV infection and type II mixed cryoglobulinemic syndrome (MC-II). Moreover, accumulating data ascribe an etiopathogenetic role in the development of B cell non-Hodgkin's lymphomas (NHL) to HCV. All these findings account for the profound effect of HCV infection in the host's immune system. The unique virus-host interactions that culminate in the generation and sustained production of autoantibodies and cryoglobulins have not been delineated. It appears that chronic antigenic stimulation could cause the emergence of specific B cell clones that produce cryoglobulins; moreover, B cell activation and/or deregulation could originate as a result of HCV binding to CD81 tetraspanin or as a consequence of its ability to replicate in B cells. In a previous study we demonstrated that, in MC-II HCV-positive patients, cryoprecipitated monoclonal IgMs, and B cell receptors (BCR) of overexpanded B cell clones share the same combinatory region. Moreover, these IgMs were reactive against both the Fc region of human IgG and the HCV-NS3 antigen. NS3 and Fc epitopes have been idengified by epitope excision approach. One of the idengified NS3 epitopes has been used to immunize a mouse and the monoclonal antibody obtained showed the same cross-reactivity as patients' IgMs. The characterization of antigenic specificity of this antibody may be useful to idengify antigens that can stimulate B cell proliferation in HCV-infected individuals.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0077-8923
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
1110
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
121-30
|
pubmed:meshHeading |
pubmed-meshheading:17911427-Animals,
pubmed-meshheading:17911427-Autoantibodies,
pubmed-meshheading:17911427-Autoantigens,
pubmed-meshheading:17911427-Carcinoma, Hepatocellular,
pubmed-meshheading:17911427-Cryoglobulinemia,
pubmed-meshheading:17911427-Genome, Viral,
pubmed-meshheading:17911427-Hepacivirus,
pubmed-meshheading:17911427-Humans,
pubmed-meshheading:17911427-Lymphatic Diseases
|
pubmed:year |
2007
|
pubmed:articleTitle |
HCV-related immunocytoma and type II mixed cryoglobulinemia-associated autoantigens.
|
pubmed:affiliation |
Farmacologia Sperimentale e Clinica DOMERT, Centro di Riferimento Oncologico, IRCCS. V.F. Gallini, 2 33081 Aviano, Pordenone, Italy.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|